📇 Rhumatologue · REIMS CEDEX · (51) · Mixte

M PATOINLOUKOUBA PROSPER KADIYOGO

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
17 articles scientifiques publiés — formation continue solide
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
134.8 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 REIMS CEDEX (51)MixteRPPS 10001741015

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

HOPITAL MAISON BLANCHE CHU REIMS
45 R COGNACQ JAY, 51092 REIMS CEDEX
☎ 0326787878Activité de soin et de pharmacie🏥 Centre CHU ↗
CABINET DU DR PATOINLOUKOUBA PROSPER KADIYOGO
38 RUE ARISTIDE BRIAND, 51350 CORMONTREUIL
☎ 0326061341

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations

Current genomics · 2014

📚 30 citations🎯 RCR 1.08🔓 Open Access

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

Stem cells translational medicine · 2021

📚 17 citations🎯 RCR 1.35🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.

Ligamentous Reconstruction of Traumatic Dislocation of Thumb Carpometacarpal Joint: Case Report and Review of Literature

Journal of orthopaedic case reports · 2015

📚 8 citations

Cookies & analyse de trafic

M PATOINLOUKOUBA PROSPER KADIYOGO

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (17) — classées par pathologie

Case report / série5

Transversal4

Revue générale3

Anti-TNF2

Lupus2

csDMARDs1

Épidémiologie & registres1

Génétique1

Ostéoporose1

Vascularites des gros vaisseaux1

Partager cette fiche